No abstract

Tumour stage helped explain socio-economic disparities in colorectal cancer survival. Disparities were also greatly attenuated among patients receiving early treatment. Aspects other than those captured by our measure of access, such as quality of care and patient preferences in relation to treatment, might contribute to a fuller explanation.

No abstract

Little is known about the economic burden associated with colorectal cancer in France. The aim of this study was to evaluate the effects of age, stage at diagnosis, health care pattern and level of comorbidities on the mean cost of the management of colorectal cancers, using data from a population-based registry and the French health care system. We estimated the direct costs of medical care for 384 colorectal cancers diagnosed in 2004, using the three main databases of the National Health Insurance. The cost of management was defined as the sum of all health expenditures over the 12 months following the date of diagnosis. The mean cost for first-year management was 24,966 euro (SE 1,195 euro). There was no significant difference in overall costs in relation to sex, age, Charlson index score, cancer location or health care pattern. Costs increased significantly with cancer extension from 17,596 euro for stage I to 35,059 euro for stage IV. Hospitalisation charges represented the greatest economic burden (55.2%), followed by medical purchases (24.4%), outpatient care (17.8%) and transportation (2.5%). These results confirm the major economic burden of colorectal cancer and indicate that total costs depend mainly on the stage at diagnosis. By improving stage at diagnosis, mass screening could contribute to decreasing the cost of managing colorectal cancers.

No abstract

Cost-effectiveness estimates and sensitivity analyses suggest that biennial screening for colorectal cancer with fecal occult blood test could be recommended from the age of 50 until 74. Our findings support the attempts to introduce large-scale population screening programs.

This study is the first one to provide fractions of diseases attributable to job strain for three health outcomes in France on the basis of a systematic review of the literature. These results could contribute to the estimation of the economic cost of diseases attributable to job strain.

Adherence of surveillance practices to French guidelines seems relatively poor. Surveillance patterns are mainly explained by patient age, tumor stage, and treatment modalities.